Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Какую позицию займет ингибитор IF-каналов ивабрадин в рекомендациях по ведению больных с хронической сердечной недостаточностью? По результатам исследования SHIFT
Какую позицию займет ингибитор IF-каналов ивабрадин в рекомендациях по ведению больных с хронической сердечной недостаточностью? По результатам исследования SHIFT
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2010; 11 (57): 3–62.
2. Swedberg K, Komajda M, Bohm M et al. on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. Published online 2010. DOI: 10.1016/S0140-6736(10) 61198-1.
3. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967–74.
4. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986; 7: 279–88.
5. Fox K, Ford I, Steg PG et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 806–16.
6. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–74.
7. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007; 9: 1205–11.
8. Dahlstrom U, Hakansson J, Swedberg K, Waldensrom A. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail 2009; 11: 92–8.
9. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005: 26: 1115–40.
2. Swedberg K, Komajda M, Bohm M et al. on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. Published online 2010. DOI: 10.1016/S0140-6736(10) 61198-1.
3. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967–74.
4. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986; 7: 279–88.
5. Fox K, Ford I, Steg PG et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 806–16.
6. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–74.
7. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007; 9: 1205–11.
8. Dahlstrom U, Hakansson J, Swedberg K, Waldensrom A. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail 2009; 11: 92–8.
9. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005: 26: 1115–40.
Авторы
Ю.М.Лопатин
Волгоградский государственный медицинский университет; Волгоградский областной кардиологический центр
Волгоградский государственный медицинский университет; Волгоградский областной кардиологический центр
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.